Updated results from the ZUMA-2 trial confirmed the therapy's benefit, including in BTKi-naïve patients, after its accelerated approval in 2020.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results